Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T17:57:40.716Z.
Calculation as of: 2026-10-06T17:57:40.716Z.
Quote observation: 2026-10-06T17:55:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e005637c0728ee7719d987fd9d1ed1bb4b4a72c9577e4c0c1fad472fb0ddb1d0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$75.75M
EBITDA Yield
9.70%
TTM Avg
5.52%
3Y Avg
5.52%
5Y Avg
5.52%
Market Cap
$79.09M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outset Medical, Inc. (OM) | $76.56M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $76.48M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $75.75M | 9.70% | 5.52% | 5.52% | 5.52% |
| Pulmonx Corporation (LUNG)vs › | $77.08M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.91M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $79.09M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.38M | N/A | N/A | N/A | N/A |
| Verrica Pharmaceuticals Inc. (VRCA)vs › | $74.73M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.14M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.47M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
